Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors
This study utilized days at home (DAH), a patient-centered metric, to assess the disease time burden in patients with advanced hepatocellular carcinoma taking systemic therapies. We demonstrated that immunotherapy was associated with higher DAH compared with tyrosine kinase inhibitor treatment, although this benefit was dampened by the occurrence of immune-related adverse events. These findings have quality-of-life implications and can be used for patient counselling.
Authors
- Rex Wan‐Hin Hui (ORCID: https://orcid.org/0000-0001-7447-7539)
- Carlos King Ho Wong (ORCID: https://orcid.org/0000-0002-6895-6071)
- Matthew Shing Hin Chung (ORCID: https://orcid.org/0000-0002-1669-4479)
- Chi‐Leung Chiang (ORCID: https://orcid.org/0000-0002-9836-6478)
- Lung‐Yi Mak (ORCID: https://orcid.org/0000-0002-2266-3935)
- Ka Shing Cheung (ORCID: https://orcid.org/0000-0002-4838-378X)
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- Ian Chi Kei Wong (ORCID: https://orcid.org/0000-0001-8242-0014)
- Xianhua Mao (ORCID: https://orcid.org/0000-0003-4050-4759)
- Wai‐Kay Seto (ORCID: https://orcid.org/0000-0002-9012-313X)
- Lu Li (ORCID: https://orcid.org/0009-0001-1145-5428)
Institutions
- Department of Health (CN)
- Aston University (GB)
- Chinese University of Hong Kong (HK)
- London School of Hygiene & Tropical Medicine (GB)
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101578
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- World Health Organization
- Gilead Sciences
- Alexion Pharmaceuticals
- Lee Foundation
- Merck KGaA
- Arrowhead Pharmaceuticals
- Sysmex Corporation
- European Commission
- Eisai
- Medical Research Council
- National Health and Medical Research Council